ANXA1 and acute myeloid leukemia: Positive immunostaining for ANXA1 protein was detected in 95.83% of AML patients, including 25% AML patients with weak expression, 41.67% with moderate expression, and 29.17% with strong expression, while there were just only 6.25% of volunteers with weak expression of ANXA1 (Figure 5B).